Process Engineer, Moderna Inc. 

Phillip Cox is a Process Engineer at Moderna, a biotechnology company advancing a new class of transformative medicines for patients in messenger RNA (mRNA). He is responsible for supporting the technical advancement of all late-stage clinical programs through commercialization. His focus is on developing, characterizing, optimizing, and implementing new innovative and robust bioprocesses for the production of mRNA-based medicines. During his time at UCLA, Phillip was an active member of BMES and Regents Scholar Society and worked at Genentech and Amgen as an undergraduate. He graduated from the UCLA Bioengineering Program in 2017, and moved to Boston, Massachusetts, where he joined Moderna when there were only 400 employees.  He has since helped Moderna expand its footprint, double in employee size, and successfully launch the largest Biotech IPO at the time. He joined the manufacturing group where he helped successfully open Moderna’s first award-winning Clinical GMP Facility. Since joining the Process Development group, he has contributed to a variety of therapeutics programs, including Infectious Diseases, Immuno-Oncology, Rare Diseases, Cardiovascular Diseases, and Autoimmune Diseases. More recently he has been supporting the rapid development and production of SARS-CoV-2, a vaccine for COVID-19.